Page 40 - Read Online

Page 14 of 14 Rabadi et al. J Cancer Metastasis Treat 2022;8:24 https://dx.doi.org/10.20517/2394-4722.2022.06

79. Tinoco R, Otero DC, Takahashi AA, Bradley LM. PSGL-1: a new player in the Immune checkpoint landscape. Trends Immunol
2017;38:323-35. DOI PubMed PMC
80. Matsumoto M, Miyasaka M, Hirata T. P-selectin glycoprotein ligand-1 negatively regulates T-cell immune responses. J Immunol
2009;183:7204-11. DOI PubMed
81. Wu H, Estrella V, Beatty M, et al. T-cells produce acidic niches in lymph nodes to suppress their own effector functions. Nat
Commun 2020;11:4113. DOI PubMed PMC
82. Molloy MGY, Rothstein J. InventorIdentification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8
modulators2016.
83. VSIG8 the Human Protein Atlas. Available from: https://www.proteinatlas.org/ENSG00000243284-VSIG8 [Last accessed on 15
June 2022].
84. Mehta N, Maddineni S, Kelly RL, et al. An engineered antibody binds a distinct epitope and is a potent inhibitor of murine and
human VISTA. Sci Rep 2020;10:15171. DOI PubMed PMC
85. Farrugia BL, Lord MS, Melrose J, Whitelock JM. The role of heparan sulfate in inflammation, and the development of biomimetics
as anti-inflammatory strategies. J Histochem Cytochem 2018;66:321-36. DOI PubMed PMC
86. Hua R, Yu J, Yan X, et al. Syndecan-2 in colorectal cancer plays oncogenic role via epithelial-mesenchymal transition and MAPK
pathway. Biomed Pharmacother 2020;121:109630. DOI PubMed
87. Popović A, Demirović A, Spajić B, Stimac G, Kruslin B, Tomas D. Expression and prognostic role of syndecan-2 in prostate cancer.
Prostate Cancer Prostatic Dis 2010;13:78-82. DOI PubMed
88. Park CH, Byun SS, An JY, et al. Abstract 1626: PMC309, a highly selective anti-VISTA antibody enhances T cell activation through
blocking the interaction of T cells and myeloid derived suppressor cells (MDSC). Cancer Res 2021;81:1626-1626. DOI
89. ElTanbouly MA, Schaafsma E, Noelle RJ, Lines JL. VISTA: coming of age as a multi-lineage immune checkpoint. Clin Exp
Immunol 2020;200:120-30. DOI PubMed PMC
90. Guillaudeux T, Iadonato S, Tarcha E, Philips C. 268 KVA 12.1 a novel fully human anti-VISTA antibody: clinical trial design in
monotherapy and in combination with an anti-PD1 antibody. J ImmunoTherapy Cancer 2021;9:A1-A1054. DOI
91. Thisted T, Mukherjee A, Malhotra K, Biesova Z, Kleschenko Y, Jiang ZG, et al. 228 Antagonistic pH-selective VISTA antibody
SNS-101 potentiates anti-PD-1/PD-L1-induced anti-tumor immunity. J ImmunoTherapy Cancer 2021. DOI
92. Pipeline iOmx therapeutics. Available from: https://iomx.com/pipeline [Last accessed on 15 June 2022].
93. A study of safety, pharmacokinetics, pharmacodynamics of JNJ-61610588 in participants with advanced cancer. Available from:
https://ClinicalTrials.gov/show/NCT02671955 [Last accessed on 15 June 2022].
94. Phase 1 study of CI-8993 anti-VISTA antibody in patients with advanced solid tumor malignancies. Available from:
https://ClinicalTrials.gov/show/NCT04475523 [Last accessed on 15 June 2022].
95. Scott F, Wichmann C, Burvenich I, McDonald A, Guo N, Rigopoulos A, et al. 324 Preclinical evaluation of anti-VISTA antibody CI-
8993 in a syngeneic huVISTA-KI model. J ImmunoTherapy Cancer 2021. DOI
96. Sasikumar PG, Sudarshan NS, Adurthi S, et al. PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical
anti-tumor efficacy. Commun Biol 2021;4:699. DOI PubMed PMC
97. Radhakrishnan V, Bakhshi S, Prabhash K, Deshmukh C, Nag S, Lakshmiah KC, et al. Abstract P714: phase 2 trial of CA-170, a
novel oral small molecule dual inhibitor of immune checkpoints VISTA and PD-1, in patients (pts) with advanced solid tumor and
Hodgkin lymphoma2018.
98. First-In-Human (FIH) Study of W0180 as single agent and in combination with pembrolizumab in adults with locally advanced or
metastatic solid tumors. Available from: https://ClinicalTrials.gov/show/NCT04564417 [Last accessed on 15 June 2022].
99. A study of HMBD-002, a monoclonal antibody targeting VISTA, as monotherapy and combined with pembrolizumab. Available
from: https://ClinicalTrials.gov/show/NCT05082610 [Last accessed on 15 June 2022].
100. Thakkar D, Paliwal S, Dharmadhikari B, et al. Rationally targeted anti-VISTA antibody that blockades the C-C' loop region can
reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc
independent manner. J Immunother Cancer 2022;10:e003382. DOI PubMed
101. Pilones KA, Hensler M, Daviaud C, et al. Converging focal radiation and immunotherapy in a preclinical model of triple negative
breast cancer: contribution of VISTA blockade. Oncoimmunology 2020;9:1830524. DOI PubMed PMC
102. Tivol EA, Borriello F, Schweitzer A, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation
and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995;3:541-7. DOI
PubMed
103. Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science
1995;270:985-8. DOI PubMed